Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric cancer in real-world patients: Updated analysis.

被引：0
|
作者：
Shimozaki, Keitaro
Fukuda, Koshiro
Ooki, Akira
Nakayama, Izuma
Yoshino, Koichiro
Udagawa, Shohei
Fukuoka, Shota
Osumi, Hiroki
Ogura, Mariko
Wakatsuki, Takeru
Takahari, Daisuke
Shinozaki, Eiji
Chin, Keisho
Yamaguchi, Kensei
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Chemotherapy, Koto Ku, Koto, Japan
[2] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[3] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[4] Canc Inst Hosp, Japanese Fdn Canc Res, Dept Advanved Med Dev, Tokyo, Japan
[5] Canc Inst Hosp, Japanese Fdn Canc Res, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.341
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：341 / 341
页数：1
相关论文
共 50 条
  • [41] Comparative efficacy and tolerability of first-line treatments for untreated, HER2-negative, advanced gastric cancer: systematic review and network meta-analysis
    Cai, Tongze
    Liang, Liuguan
    Zhao, Xingxing
    Lin, Caiyue
    Li, Dandan
    Zheng, Jinghui
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 193
  • [42] Efficacy of rechallenge after first-line immunotherapy for advanced gastric cancer: A retrospective real-world study
    Guo, Mengya
    Zhao, Wenhui
    Chen, Yue
    Zou, Dan
    Peng, Weiwei
    Sha, Huanhuan
    Zhou, Guoren
    Fang, Ying
    Shen, Bo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [43] Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients: A Real-World Analysis
    Zurlo, Ina Valeria
    Pozzo, Carmelo
    Strippoli, Antonia
    Mignogna, Samantha
    Basso, Michele
    Vivolo, Raffaella
    Trovato, Giovanni
    Ciaburri, Michele
    Morelli, Franco
    Bria, Emilio
    Leo, Silvana
    Tortora, Giampaolo
    GERIATRICS, 2022, 7 (05)
  • [44] Updated efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer
    Kong, Y.
    Dong, Q.
    Jin, P.
    Li, M.
    Ma, L.
    Yi, Q.
    Miao, Y-E.
    Liu, J.
    Liu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1467 - S1467
  • [45] Real-world efficacy and safety of palbociclib combined with fulvestrant in japanese patients with ER-positive HER2-negative advanced or metastatic breast cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Shimizu, Ken
    Higeta, Kaori
    CANCER RESEARCH, 2020, 80 (04)
  • [46] Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
    Matsuda, Naoko
    Wang, Xiaoping
    Lim, Bora
    Krishnamurthy, Savitri
    Alvarez, Ricardo H.
    Willey, Jie S.
    Parker, Charla A.
    Song, Juhee
    Shen, Yu
    Hu, Jianhua
    Wu, Wenhui
    Li, Nan
    Babiera, Gildy V.
    Murray, James L.
    Arun, Banu K.
    Brewster, Abenaa M.
    Reuben, James M.
    Stauder, Michael C.
    Barnett, Chad M.
    Woodward, Wendy A.
    Le-Petross, H. T. Carisa
    Lucci, Anthony
    DeSnyder, Sarah M.
    Tripathy, Debu
    Valero, Vicente
    Ueno, Naoto T.
    JAMA ONCOLOGY, 2018, 4 (09) : 1207 - 1213
  • [47] A real world retrospective study of advanced gastric cancer patients treated with nivolumab plus chemotherapy
    Komoda, M.
    Okumura, Y.
    Arimizu, K.
    Matsumura, T.
    Nishijima, T.
    Esaki, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1370 - S1370
  • [48] Clinical efficacy and safety of paclitaxel liposomes as first-line chemotherapy in advanced gastric cancer
    Han, Guangjie
    Shi, Jianfei
    Mi, Lili
    Li, Ning
    Shi, Huacun
    Li, Cuizhen
    Shan, Baoen
    Yin, Fei
    FUTURE ONCOLOGY, 2019, 15 (14) : 1617 - 1627
  • [49] Real-world efficacy of ribociclib plus aromatase inhibitor/fulvestrant, or endocrine monotherapy, or chemotherapy as first-line treatment in women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Third interim analysis from the RIBANNA study
    Wockel, Achim
    Brucker, Cosima
    Decker, Thomas
    Falbrede, Jorg
    Forstbauer, Helmut
    Gohler, Thomas
    Hoffmann, Oliver
    Jackisch, Christian
    Janssen, Jan
    Kohler, Andreas
    Ludtke-Heckenkamp, Kerstin
    Luftner, Diana
    Marme, Frederik
    Nusch, Arnd
    Reimer, Toralf
    Roos, Christian
    Schmidt, Marcus
    Weide, Rudolf
    Fasching, Peter
    CANCER RESEARCH, 2021, 81 (04)
  • [50] Real-world efficacy of ribociclib plus aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Second interim analysis from the RIBANNA study
    Woeckel, Achim
    Basiora, Pawel
    Bohlmann, Michael
    Decker, Thomas
    Falbrede, Joerg
    Fasching, Peter
    Forstbauer, Helmut
    Hesse, Tobias
    Hoffmann, Oliver
    Jackisch, Christian
    Kaczerowsky, Anna
    Lorenz, Ralf
    Luedtke-Heckenkamp, Kerstin
    Lueftner, Diana
    Marme, Frederik
    Mueller, Thomas
    Mundhenke, Christoph
    Nusch, Arnd
    Petersen, Volker
    Prange-Krex, Gabriele
    Reimer, Toralf
    Resch, Thomas
    Roos, Christian
    Tome, Oliver
    Weishap, Anja
    CANCER RESEARCH, 2020, 80 (04)
12345